<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62024">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840436</url>
  </required_header>
  <id_info>
    <org_study_id>CT11M10MURT</org_study_id>
    <nct_id>NCT01840436</nct_id>
  </id_info>
  <brief_title>Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer</brief_title>
  <acronym>MUCIPLIQ</acronym>
  <official_title>A Randomized Controlled Study Evaluating the Effect of MUCIPLIQ Versus Placebo on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering of Upper Aerodigestive Tract Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Organ, Tissue, Regeneration, Repair and Replacement</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Organ, Tissue, Regeneration, Repair and Replacement</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Conseil National de l'Ordre des Médecins</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MUCIPLIQ is a nanopolymer engineered to mimic glycosaminoglycans such as heparan sulfates.
      Glycosaminoglycans are involved 1) in the stabilization of cells micro-environment, known as
      extracellular matrix, by binding to structural proteins, and 2) in cells communication
      process by protecting growth factors. At the site of a lesion, glycosaminoglycans are
      degraded, thereby the extracellular matrix is disorganized and the tissue is destroyed. By
      replacing damaged glycosaminoglycans, MUCIPLIQ provides a protection, and restores the
      matrix scaffold and cells communication, a process known as Matrix Therapy.

      The purpose of this new controlled study is to determine whether MUCIPLIQ can decrease the
      incidence and the severity of radio-chemotherapy-induced mucositis in patients suffering of
      upper aerodigestive tract cancers, when used as a preventive agent.

      The study's main hypothesis is that MUCIPLIQ mouthwash applications before radiotherapy
      would protect the healthy oral tissue against cytotoxic effect of chemotherapy and
      radiations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of grade 2 or higher oral mucositis</measure>
    <time_frame>Recruitment, 2, 3, 4, 5, 6, 7 and 11 to 13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences of incidence of patients suffering of oral mucositis of grade 2 or higher</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Terms of grade 2 or higher oral mucositis</measure>
    <time_frame>Recruitment, 2, 3, 4, 5, 6, 7 and 11 to 13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences of number and terms of oral mucositis of grade 2 or higher between MUCIPLIQ and placebo groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administered-antalgics posology and nature</measure>
    <time_frame>Recruitment, 2, 3, 4, 5, 6, 7 and 11 to 13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences of administered-antalgics posology and nature between MUCIPLIQ and placebo groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain experienced in time</measure>
    <time_frame>Recruitment, 2, 3, 4, 5, 6, 7 and 11 to 13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences of pain experienced by patients between MUCIPLIQ and placebo groups, assessed with Numerical Pain Scale (0 to 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the Oral Health Impact Profile</measure>
    <time_frame>Recruitment, 2, 3, 4, 5, 6, 7 and 11 to 13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of the Oral Health Impact Profile assessed by the OHIP-14 questionnaire between MUCIPLIQ and placebo groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight curve</measure>
    <time_frame>Recruitment, 2, 3, 4, 5, 6, 7 and 11 to 13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of the weight curves for MUCIPLIQ and placebo groups</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Oral Mucositis</condition>
  <condition>Carcinoma in Situ of Upper Respiratory Tract</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm receives a placebo (saline solution) mouthwash treatment twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MUCIPLIQ 0.05 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.05 mg/mL twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MUCIPLIQ 0.015 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.015 mg/mL twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MUCIPLIQ</intervention_name>
    <description>MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.</description>
    <arm_group_label>MUCIPLIQ 0.05 mg/mL</arm_group_label>
    <arm_group_label>MUCIPLIQ 0.015 mg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient suffering from an upper aerodigestive tract carcinoma treated by radiotherapy
             alone or radiotherapy associated with a concomitant platine-salts-based chemotherapy
             ;

          -  Patient suffering of an upper aerodigestive tract carcinoma without entrance or
             located in the oral cavity, in the oropharynx or in the rhinopharynx ;

          -  Patient age of 18 years old or higher ;

          -  Writing informed consent to participate to the trial ;

          -  Patient affiliated to the French social security system.

        Exclusion Criteria:

          -  Treatment by non-standard fragmentation (concentrate irradiation)

          -  Carcinoma located in the hypopharynx or in the larynx ;

          -  Known hypersensitivity to heparinoids ;

          -  Patient who already benefited from a radiotherapy treatment ;

          -  Patient who already benefited from a chemotherapy treatment. Patients who benefited
             from neoadjuvant chemotherapy as part of their upper aerodigestive tract carcinoma
             care, may be included if it was held at least 4 weeks before the inclusion visit ;

          -  Patient participating to another biomedical research ;

          -  Pregnant woman, breastfeeding woman, parturient or likely to be ;

          -  Patient deprived of freedom, under supervision or guardianship ;

          -  Patient unable to attend to scheduled medical monitoring due to geographical, social
             or mental reasons
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Daly-Schveitzer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy, Villejuif, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yungan Tao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy, Villejuif, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stéphanie Filipe, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Organ, Tissue, Regeneration, Repair and Replacement</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphanie Filipe, PhD</last_name>
    <phone>+33 (0)1 83 62 85 43</phone>
    <email>stephanie.filipe@otr3.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ketty Kichenin, PhD</last_name>
    <phone>+33 (0)1 83 62 85 44</phone>
    <email>ketty.kichenin@otr3.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <state>Ile de France</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Martin, MD</last_name>
      <phone>+ 33 (0)1 45 17 52 10</phone>
      <email>michel.martin@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephane Henault, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Malaurie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Huguet, MD</last_name>
      <phone>+33 (0)1 56 01 83 22</phone>
      <email>florence.huguet@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Huguet, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gianandroa Pietta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Ile de France</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yungan Tao, MD, PhD</last_name>
      <phone>+33 (0)1 42 11 47 57</phone>
      <email>yungan.tao@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pierre Blanchard, MD</last_name>
      <phone>+33 (0)1 42 11 47 57</phone>
      <email>pierre.blanchard@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Yungan Tao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Blanchard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Cancérologie Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Séverine Racadot, MD</last_name>
      <phone>+33 (0)4 78 78 59 06</phone>
      <email>severine.racadot@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Séverine Racadot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Montbarbon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal Pommier, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Besançon, Site du CH Belfort-Montbéliard</name>
      <address>
        <city>Montbéliard</city>
        <zip>25200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu-Shan Sun, MD</last_name>
      <phone>+33 (0)3 81 98 88 44</phone>
      <email>xssun@chbm.fr</email>
    </contact>
    <investigator>
      <last_name>Xu-Shan Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yasser Hammoud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MUCIPLIQ</keyword>
  <keyword>Matrix therapy</keyword>
  <keyword>RGTA</keyword>
  <keyword>Oral mucositis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
